Condition: Febrile Neutropenia · Sponsor: University Health Network, Toronto
Infections are a common complication in patients with cancer. They are a significant cause of complications and death in this population. Patients with cancer and low neutrophil counts due to chemotherapy or disease often have a fever and receive antibiotic treatment. The optimal duration of this treatment is largely unknown. Late, there have been some data suggesting the safety of early discontinuation of antibiotics, though most centers still give more prolonged antibiotic therapies in this situation. The unnecessary prolonged antibiotic use may increase infections with multi-drug-resistant bacteria, which carry a high death rate. Also, an increase in infections caused by Clostridioides difficile and an increase in fungal infections can happen. However, some are concerned that stopping antibiotics while the neutrophil count is still low will result in life-threatening infections. Our study aims to test whether shorter antibiotic treatment in these situations is as safe as more prolonged treatment, resulting in better antibiotic prescription practices in this population.
This description comes directly from the study's public registry record.
Shahid Husain, MD · 4163404800 · shahid.husain@uhn.ca
Roni Bitterman, MD · 4163404800 · roni.bitterman@uhn.ca
Always discuss trial participation with your own doctor first.
| Alberta Health Services | Edmonton, Canada | Recruiting |
| London Health Sciences Centre | London, Canada | Recruiting |
| University Health Network | Toronto, Canada | Recruiting |
| Vancouver General Hospital | Vancouver, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05786495